IL18 and myeloid sarcoma: Significant reduction of body weight, hs-CRP, IL-6, IL-7, IL-18 and insulin resistance in intervention group. Endothelial function score improved in the intervention group. MD might be effective at reducing the prevalence of MS and its associated cardiovascular risk.